| Nov 7 |
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
|
| Nov 5 |
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
|
| Nov 4 |
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
|
| Oct 16 |
Cullinan gets FDA clearance for Phase 1 lupus study for CLN-978
|
| Oct 16 |
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
|
| Sep 17 |
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
|
| Sep 16 |
Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus
|
| Sep 14 |
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
|
| Aug 30 |
Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease
|
| Aug 28 |
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
|
